274 related articles for article (PubMed ID: 34556152)
21. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
23. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.
Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y
Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298
[TBL] [Abstract][Full Text] [Related]
24. Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen.
Adotévi O; Galaine J
Cancer Res; 2022 Jul; 82(14):2517-2519. PubMed ID: 35844172
[TBL] [Abstract][Full Text] [Related]
25. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
[No Abstract] [Full Text] [Related]
26. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
28. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
29. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
30. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
31. Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.
Wu S; Wang B; Li H; Wang H; Du S; Huang X; Fan Y; Gao Y; Gu L; Huang Q; Chen J; Zhang X; Huang Y; Ma X
Oncogene; 2024 May; 43(20):1534-1548. PubMed ID: 38548966
[TBL] [Abstract][Full Text] [Related]
32. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R
Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471
[TBL] [Abstract][Full Text] [Related]
33. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
Tykodi SS; Satoh S; Deming JD; Chou J; Harrop R; Warren EH
J Immunother; 2012 Sep; 35(7):523-33. PubMed ID: 22892449
[TBL] [Abstract][Full Text] [Related]
34. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.
Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ
Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.
Xu DD; Ding M; Tong P; Chong YY; Gu WY; Li Y; Fang XJ; Li N
Oncol Rep; 2020 Sep; 44(3):897-908. PubMed ID: 32705278
[TBL] [Abstract][Full Text] [Related]
36. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.
Dong Q; Yu T; Chen B; Liu M; Sun X; Cao H; Liu K; Xu H; Wang Y; Zhuang S; Jin Z; Liang H; Hui Y; Gu Y
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937640
[TBL] [Abstract][Full Text] [Related]
37. Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ; Lee YH; Koo KC
Investig Clin Urol; 2022 Sep; 63(5):486-498. PubMed ID: 36067994
[TBL] [Abstract][Full Text] [Related]
38. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Chen P; Nogusa S; Thapa RJ; Shaller C; Simmons H; Peri S; Adams GP; Balachandran S
PLoS One; 2013; 8(4):e61446. PubMed ID: 23613854
[TBL] [Abstract][Full Text] [Related]
40. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes.
Diegmann J; Junker K; Loncarevic IF; Michel S; Schimmel B; von Eggeling F
Neoplasia; 2006 Nov; 8(11):933-8. PubMed ID: 17132225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]